Private Equity focused on Longevity & Hormone health
Delivering exceptional outcomes for doctors, patients and our investors.
Private Equity focused on Longevity & Hormone health
Delivering exceptional outcomes for doctors, patients and our investors.
About PEAL Capital
We Partner with the medical community to expand their operations
PEAL Capital (“PEAL”) is a Swiss private equity firm that invests in healthcare, with a focus on longevity and hormone health (“L&H”). We have investments in the UK, Europe, Australia and North America. We take controlling stakes in growing lower-mid-cap businesses and deliver hands-on operational and financial support from acquisition through to exit.
Years of experience
85+ years combined industry expertise
49 direct investment exits
2.46× MOIC
Our Mission
To improve the healthspan of women everywhere by closing the gap in hormone care: training the best clinicians, treating patients at scale and building the evidence base that makes effective, affordable treatment the norm.
Our Values
We believe in disciplined execution, full alignment with the management teams we back and growth that lasts. We hold ourselves to integrity and transparency in everything we do, and we build partnerships that outlive any single deal.
Reasons to Choose Us
Why Investors Choose PEAL Capital
PEAL invests across the whole supply chain through a three-fund strategy, from clinician training to clinics to hormone supply. That focus gives us access to proprietary, off-market deals and gives investors exposure to the full sector in one place.
Proprietary deal flow through trusted clinical and founder networks
Due diligence built on historical and live data, not projections
Hands-on value creation across every function of the business
Clear exit strategies with staged holding periods
Full alignment with management teams and the patients they treat
A track record of consistent, risk-adjusted returns
Reasons to Choose Us
Why Investors Choose PEAL Capital
PEAL invests across the whole supply chain through a three-fund strategy, from clinician training to clinics to hormone supply. That focus gives us access to proprietary, off-market deals and gives investors exposure to the full sector in one place.
Proprietary deal flow through trusted clinical and founder networks
Due diligence built on historical and live data, not projections
Hands-on value creation across every function of the business
Clear exit strategies with staged holding periods
Full alignment with management teams and the patients they treat
A track record of consistent, risk-adjusted returns
Investment Track Record
Successful Exits
Net MOIC/IRR
Net MOIC/IRR
Investement Track Record.
Successful Exits
Net MOIC/IRR
Net MOIC/IRR
Meet Our Team
A Trusted Team With Decades of Investment and Operational Experience
Karen O'Mahony
Founder & Managing Partner
Brendan McDonagh
Chair of PEAL Capital Group
Lynda Hayden
Partner & COO
Want to join our team?
News
News and Insights from the PEAL Capital Group
DermaHub Launch
On 1st November 2023, Derma Medical launched the world’s first e-learning hub for Aesthetics professionals. DermaHub will be the first of its kind to offer a subscription-based platform that will allow delegates to access the highest-quality online training from...
TAIC Meet-Up
Karen O'Mahony attends The Alternative Investment Club's Meet-Up, LONGEVITY: Not Only Living Longer but Better PEAL's Managing Partner, Karen O'Mahony, thoroughly enjoyed sharing her insights on Longevity alongside the panel at The Alternative Investment Club's...
Private Equity International Operating Partners Forum
Karen O'Mahony spoke about building agility in the current economy and the next chapter of the value creation playbook at the PEI conference. At the Private Equity International Operating Partners Forum, Karen O'Mahony spoke about building agility in the current...